| Literature DB >> 32435368 |
Alessio Molinari1, Giulia Iovenitti1, Arianna Mancini1,2, Giovanni Luca Gravina3, Monia Chebbi1,4, Maura Caruana1, Giulia Vignaroli1, Francesco Orofino1, Enrico Rango1, Adriano Angelucci3, Elena Dreassi1, Silvia Schenone5, Maurizio Botta1,6,7.
Abstract
Gold-nanoparticle (AuNP)-conjugated drugs represent a promising and innovative antitumor therapeutic approach. In our study, we describe the design, the synthesis, the preparation, and the characterization of AuNPs conjugated with the pyrazolo[3,4-d]pyrimidine derivative SI306, a c-Src inhibitor. AuNPs-SI306 showed a good loading efficacy (65%), optimal stability in polar media and in human plasma, and a suitable morphological profile: a ζ-potential of -43.9 mV, a nanoparticle diameter of 48.6 nm, and a 0.441 PDI value. The antitumoral activity of AuNPs-SI306 was evaluated in vitro in the glioblastoma model, by the low-density growth assay, and also in combination with radiotherapy (RT). Results demonstrated that AuNPs had a basal radiosensitization ability and that AuNPs-SI306, when used in combination with RT, were more effective in inhibiting tumor cell growth with respect to AuNPs and free SI306.Entities:
Year: 2020 PMID: 32435368 PMCID: PMC7236040 DOI: 10.1021/acsmedchemlett.9b00538
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345